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Abstract 
 
Context: Recurrence of hypercortisolism in patients after bilateral adrenalectomy for Cushing’s 
disease is extremely rare.  
  
Patient: We present a rare case of a 27-year-old man who previously underwent bilateral 
adrenalectomy for Cushing’s disease with complete clinical resolution. Cushingoid features recurred 
12 years later, along with bilateral testicular enlargement. Hormonal tests confirmed ACTH-
dependent Cushing’s. Surgical resection of the testicular tumors led to clinical and biochemical 
remission. 
 
Design and Results: Gene expression analysis of the tumor tissue by qPCR showed high expression of 
all key steroidogenic enzymes. Adrenocortical-specific genes were 5.1 x 105 (CYP11B1), 1.8 x 102 
(CYP11B2) and 6.3 x 104 (MC2R) times higher than non-steroidogenic fibroblast control. This 
correlated with urine steroid metabolome profiling showing 2-5 fold increases in the excretion of the 
metabolites of 11-deoxycortisol, 21-deoxycortisol and total glucocorticoids. Leydig-specific genes 
were 4.3 x 101 (LHCGR) and 9.3 x 100 (HSD17B3) times higher than control and urinary steroid 
profiling showed 2-fold increased excretion of the major androgen metabolites androsterone and 
etiocholanolone. These distinctly increased steroid metabolites were suppressed by dexamethasone, 
but unresponsive to hCG stimulation, supporting the role of ACTH, but not LH, in regulating tumor-
specific steroid excess. 
 
Conclusion: We report bilateral testicular tumors occurring in a patient with recurrent Cushing’s 
disease 12 years after bilateral adrenalectomy. Using mRNA expression analysis and steroid 
metabolome profiling, the tumors demonstrated both adrenocortical and gonadal steroidogenic 
properties, similar to testicular adrenal rest tumors found in patients with congenital adrenal 
hyperplasia. This suggests the presence of pluripotent cells even in patients without CAH. 
 
  
Introduction 
 
Bilateral adrenalectomy is considered a definitive cure for Cushing’s disease, but some patients may 
have residual adrenal function from post-surgical remnants or ectopic adrenal tissue (1,2). Rarely, 
patients with Nelson’s syndrome (and high ACTH levels) after bilateral adrenalectomy, have been 
reported to develop testicular tumors, with variable cortisol and androgen production (3-5). Some 
tumors were removed due to symptoms of mass effects but detailed molecular investigations were 
not conducted.  
 
In contrast, testicular adrenal rest tumors (TART) are seen in up to 94% of male patients with 
congenital adrenal hyperplasia (CAH), with increasing prevalence during adolescence (6,7). Elevated 
ACTH levels, and possibly LH, may play a role in its development (8). We recently demonstrated that 
TART have both adrenocortical and Leydig cell features, suggesting a pluripotent embryonic cell 
origin (9).  
 
We report a rare case of bilateral testicular tumors resulting in recurrent hypercortisolism in a 
patient with Cushing’s disease who had previously undergone bilateral adrenalectomy. We 
characterized the steroidogenic potential of these tumors by mRNA expression analysis and serum 
and urinary steroid profiling. Our findings demonstrate that the tumor tissue featured both adrenal 
and gonadal steroidogenic properties, resembling TART tissue found in CAH patients.  
 
Case Report 
 
An 11-year-old boy presented with rapid weight gain, rounded facies, and abdominal striae. He was 
diagnosed with Cushing’s disease, and underwent trans-sphenoidal removal of a corticotrophin-
producing pituitary adenoma. Recurrence occurred within the first post-operative year, and after 
failure of both radiotherapy and ketoconazole to control his symptoms, he underwent bilateral 
adrenalectomy four years later (age 15 years), resulting in undetectable serum cortisol after ACTH 
stimulation (<20 nmol/L). Spontaneous pubertal development ensued. One year later, he developed 
Nelson’s syndrome (hyperpigmentation with ACTH 1089 pmol/L) and pituitary apoplexy requiring 
trepanation and partial extirpation. Subsequently, the pituitary tumor remained stable in size, ACTH 
levels ranging from 158–2921 pmol/L, while receiving hydrocortisone 25mg and fludrocortisone 
0.1mg daily. 
 
At the age of 27 years, twelve years post-adrenalectomy, he experienced increased lethargy and 
weight gain over a period of 6 months. He had a Cushingoid habitus and abdominal striae. His testes 
were nodular, hard, and enlarged bilaterally. Corticosteroid replacement was stopped, and recurrent 
ACTH-dependent Cushing’s syndrome was confirmed biochemically (Table 1). MRI imaging showed a 
small, stable pituitary remnant. Ultrasound and MRI of the testes revealed a single, large right 
testicular tumor, and multiple left testicular tumors with a small remnant of normal tissue (Fig. 1A+B). 
Abdominal CT showed a small nodule (<1cm) in the left adrenal region, suggesting incomplete 
surgical resection or post-surgical scar tissue. Semen analysis showed azoospermia.  
 
He underwent bilateral testicular nodulectomy, with preservation of his left residual normal 
testicular tissue (Fig. 1C+D). One week after surgery, early-morning 8am cortisol was undetectable 
(<20 nmol/L) (Table 1). His symptoms resolved, and he was started on corticosteroid and 
testosterone replacement. 
 
Materials and Methods 
 
Detailed Materials and Methods are described in the Supplemental Appendix. Written informed 
consent with permission for publication was obtained from the patient, and the study was approved 
by the local ethics committee.” 
Results 
 
Serum and urine steroid metabolite profiling, before and after surgery 
Serum and urine were collected at baseline, after high-dose dexamethasone suppression test (HDDST) 
and after hCG stimulation. Serum cortisol and its precursors (11–deoxycortisol, 17-
hydroxyprogesterone), and androstenedione were elevated at baseline, suppressed by HDDST, and 
unresponsive to hCG stimulation (Table 1). Levels were undetectable after surgery. Testicular vein 
sampling performed during surgery demonstrated excess steroid production bilaterally (Table 1).  
 
Urine steroid metabolite profiling (Fig. 1E) showed increased excretion of glucocorticoid metabolites, 
androgen metabolites (etiocholanolone) as well as precursor steroid metabolites from all three 
steroidogenic pathways. The metabolites of 11-deoxycortisol and 21-deoxycortisol were increased up 
to 5-fold, while 17-hydroxyprogesterone metabolites were increased >10-fold of the upper reference 
range. Interestingly, DHEA, reflective of the classic androgen synthesis pathway, was low. In contrast, 
there was highly increased excretion of the alternative androgen pathway intermediates 3,5-17-
hydroxyprogesterone (485 g/24h; control group median 26 (range 5-118) g/24h) and 11-hydroxy-
androsterone (15,766 g/24h; control 588 (181-1290) g/24h).  
By comparison, urine steroid metabolite profiling of two newly diagnosed and hence untreated 
adolescent patients with 21-hydroxylase deficiency demonstrated a similar pattern of increased 
steroid metabolites, in particular those derived from progesterone, 17-hydroxyprogesterone, 21-
deoxycortisol and alternative pathway metabolites 3,5-17-hydroxyprogesterone and 11beta-
hydroxy-androsterone.  Conversely, these changes were not observed in two adult patients with 
Cushing’s disease, who predominantly excreted increased amounts of corticosterone, 11-
deoxycortisol and in particular cortisol metabolites (Fig.1E). Thus the steroid excretion pattern 
observed in our patient resembled a combination of both CAH and Cushing’s disease.  
 
Gene expression analysis of right testicular tumor tissue 
Using qPCR quantification (Fig. 1F), the expressions of adrenal cortex-specific genes were 5.1 x 105 
(CYP11B1), 1.8 x 102 (CYP11B2), and 6.3 x 104 (MC2R) times higher in the patient’s tumor tissue 
compared to the non-steroidogenic control (fibroblast), whereas the expression for AGTR2 was 2 
times lower. Genes common to both adrenal and testis tissue were 3.8 x 105 (CYP17A1), 2.1 x 104 
(HSD3B2) times higher, and Leydig cell genes were 4.3 x 101 (LHCGR), 9.3 (HSD17B3) times higher 
compared with non-steroidogenic control. Compared to TART samples from CAH patients that we 
had previously similarly analyzed (9), the patient’s tumor was above the interquartile range (IQR) for 
glucocorticoid-related factors (CYP11B1, MC2R), and below the IQR for androgen-related factors 
(LHCGR, and HSD17B3).  
 
Discussion 
 
In this rare case of bilateral testicular tumors causing recurrence of Cushing’s syndrome after 
bilateral adrenalectomy, we were able to demonstrate by gene expression and steroid metabolome 
studies that the tumor tissue has shared adrenocortical and gonadal steroidogenic properties.  
 
TART are historically considered to originate from adrenal rests descending together with the testes 
during embryonic development (8). However, we recently found evidence that they develop from 
pluripotent cells within the testes with adrenal and Leydig cell features (9). Our patient’s tumor 
shared morphological and biochemical features with adrenal tissue, Leydig cell tumors, and virilizing 
adrenocortical tumors, illustrating the difficulty of differentiating adrenocortical cells from Leydig 
cells. 
 
In a previous similar case, Hamwi (10) demonstrated via in vitro studies that the testicular tumor in a 
patient with recurrent Cushing’s was able to produce cortisol and cortisone, although it did not 
produce androgens. We now demonstrated expression of adrenal-specific genes in the tumor tissue, 
and correlated this with increased glucocorticoid excretion. In addition, androgen excretion from 
both classic and alternative synthesis pathways (11,12) was significantly increased, although relative 
gene expression of Leydig cell-specific genes was only slightly increased. Interestingly, the steroid 
excretion profile of the TART tumor in this patient resembled a combination of steroid excretion in 
CAH and Cushing’s disease with ACTH-mediated stimulation of intact steroidogenesis.   
It is postulated that chronically elevated ACTH, LH and angiotensin II contribute to differentiation of 
the early cell (even pre-natally), and TART development (8,13,14). In our patient, response to 
dexamethasone, and high MC2R expression support the role of ACTH, that was persistently elevated. 
However, in this case, exposure was only post-natal, suggesting the presence of pluripotent cells 
within the testes also in post-natal life and adulthood. Conversely, no cases of post-bilateral 
adrenalectomy TART development have been described in adults older than 23 years, suggesting that 
regression of pluripotent cells ensues shortly after puberty. 
There was relatively higher expression of CYP11B1 and MC2R, but lower expressions of HSD17B3 and 
LHCGR, compared to TART in CAH patients (9). This suggests that our patient’s tumor was more 
adrenal-like, while TART in CAH patients are more Leydig cell-like, similar to other findings (3,10). It 
has also been suggested that LH surge during puberty is important for TART development and 
progression in CAH patients (6). Although our patient had low relative expression of LHCGR, and no 
response to hCG, he entered into puberty soon after adrenalectomy, where he was exposed to high 
LH levels. Hence, it remains conceivable that early pre-pubertal LH stimulation of testicular tissue 
contributed to TART development.  
 
In conclusion, we present a rare case of recurrent Cushing’s disease after bilateral adrenalectomy 
from testicular tumors with adrenal and Leydig cell-specific features. Endocrinologists should 
consider this possibility if symptoms recur after adrenalectomy, while patients are on maintenance 
steroids. Further research is needed to understand the mechanism of development of these 
testicular tumors. 
 
  
  
 
Figure 1.  
A. MRI Axial T2 turbo inversion recovery magnitude (TIRM) image showing the irregular tumor in the 
right testis (R), surrounded by a rim of normal testicular tissue (*) and the tumor in the left testis (L). 
B. Sagittal ultrasound image showing the irregular mass in the right testis (R), surrounded by a rim of 
normal testicular tissue (*).  
C. Macroscopically, both right and left tumors were nodular brown homogeneous tumors, partly 
encapsulated, measuring up to 5 respectively 6 cm.  
D. Microscopically, the tumors were located in and near the rete testis (asterix). They had a 
multinodular aspect consisting of sheets or confluent cords of large polygonal cells with abundant 
eosinophilic cytoplasm, which infiltrated in between seminiferous tubules, into the rete testis and 
sporadically intravascular. No other criteria for malignancy (mitosis, necrosis) were met. Incomplete 
spermatogenesis with maturation arrest at the primary spermatocytic level was seen in the 
surrounding seminiferous tubules.  
E. Heat map depicting results of 24h urine steroid metabolite profiling at baseline, after high-dose 
dexamethasone suppression test (HDDST), after hCG stimulation, and after surgical removal of 
testicular tumors. Red indicates excretion amounts higher than the adult male reference range, and 
blue indicates decreased levels. For comparison, 24 urine steroid profiling from two adult male 
patients with ACTH-dependent Cushing’s syndrome and two adolescent patients (male on the left, 
female on the right) with non-classic 21-hydroxylase deficiency are also displayed. 
 
F. Gene expression profile of 8 markers measured in Testicular Adrenal Rest Tumors (TART) of 
congenital adrenal hyperplasia (CAH) patients (9) (black) and the right testis tumor of the patient 
(red). The genes were subdivided into common genes for both adrenal cortex and Leydig cells of the 
testis, adrenocortical specific genes (including mineralocorticoids and glucocorticoids), and Leydig 
cell specific genes. Symbols and error bars in the graph represent median and 25th and 75th percentile 
of all normalized relative expression values.  
Table 1 . Serum hormones and steroids during dynamic tests, testicular venous sampling and post-surgery. 
 Baseline 
a
 Dynamic Testing  Testicular Venous sampling 
d
  Post-
Surgery 
e
 
 Reference range 
  Baseline Post-
HDDST 
b
 
Post- hCG
c
  Peripheral 
vein 
Left 
testicular 
vein 
Right 
testicular 
vein 
    
24hr urinary free 
cortisol 
1020           20 – 135 nmol/24hr 
Midnight salivary 
cortisol 
5.6           <2.2nmol/L 
ACTH 193 293 181 282      1010  2.2 – 13.2 pmol/L 
Renin  27 46 78      54  4.4 – 85 mU/L 
FSH  0.18 0.15 0.19      4.9  1.5 – 11 U/L 
LH  <0.10 <0.10 <0.10      2.8  1.4 – 8.5 U/L 
Inhibin B  63.1 60.9 69.6      <10  150 – 400 ng/L 
Progesterone  3.8 1.0 4.8  2.1 15 69  0.020  <1.3 nmol/L 
Corticosterone  14.1 9.2 19.2  27.4 35.5 337  2.6  5.8 – 56 nmol/L 
Aldosterone  <0.09 0.12 0.10  0.43 NA 
f
 0.89  <0.03  0.08 – 0.69 nmol/L 
17-hydroxy-
pregnenolone 
 4.17 3.15 3.33  NA 
f
 NA 
f
 NA 
f
  NA  0.9 – 10.5 nmol/L 
17-hydroxy-
progesterone 
 126 38 165  85 880 1780  <0.070  2.0 – 10.8 nmol/L 
11-deoxycortisol  6.1 1.5 6.6  4.0 111 136  <0.17  0.2 – 4.3 nmol/L 
Cortisol  530
 g
 180
 g
 570
 g
  230 2730 2650  <20  190 – 550 nmol/L 
DHEA  2.4 1.3 2.4  1.7 2.1 15.1  <0.2  15 – 45 nmol/L 
DHEAS  3.8 2.8 4.2  2.8 NA 
f
 4.1  <0.41  1 – 7 umol/L 
Androstenedione  58 21 63  36 390 790  <0.060  1.15 – 4.7 nmol/L 
Testosterone  27.0 10.1 27.1  16.9 658 443  <0.1  11.0 – 45.0 nmol/L 
5α-dihydro-
testosterone 
 2.19 1.39 2.39  1.61 NA 
f
 5.31  <0.098  1 – 2.9 nmol/L 
Estrone  470 370 430  NA 
f
 NA 
f
 NA 
f
  NA  80 – 250 pmol/L 
Oestradiol  80 67 57  81 74 210  25  75 – 220 pmol/L 
11deoxy-
corticosterone  
 NA NA NA  <0.30 0.43 11.7  NA   
a 
Baseline tests were done after exogenous glucocorticoids and mineralocorticoids had been stopped for a week. 
b
 Dexamethasone was administrated orally as 2mg every 6 hours for 48 hr, with investigations done at 8am on the third day, 6 hours after last dose.  
c
 Daily IM injections of 1500 U hCG were administered subcutaneously on 3 consecutive days at 8 am 
d 
Testicular vein sampling done during surgery.
 
Testicular veins were cannulated prior to surgical removal. Peripheral sample was taken from a cubital vein during the sampling
 
e 
taken 1 week after surgery, 24 hr after last hydrocortisone dose. 
f
 levels not taken due to inadequate serum volume collected. 
g
 cortisol levels done with immunoassay. Other cortisol levels are measured with LCMSMS 
ACTH, adrenocorticotropic hormone; FSH, follicle-stimulating hormone; LH, luteinizing hormone; DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulfate; NA not available
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